Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports.

Abstract

INTRODUCTION:

Cerebellar mutism syndrome (CMS) is a common complication after posterior fossa tumor resection. It is characterized by a significant lack or loss of speech. Its biological origin remains unclear and there are no standardized treatments. However, bromocriptine seems to be a possible treatment for this condition.

CASE REPORT:

In this paper, we present three cases of pediatric patients (4, 5, and 17-year old) who developed CMS after posterior fossa tumor surgery. They were treated with bromocriptine to improve neurological symptoms.Management and outcome: Bromocriptine was started at a low dose and was progressively increased to reach the minimum effective dose. After four months of treatment, a normal and fluid speech was observed in the three patients. No discontinuation due to adverse events were reported.

DISCUSSION:

Bromocriptine has shown to be an effective and safe treatment for CMS in pediatric patients after posterior fossa tumor resection.

• Authors: Miguel Á Amor-García, Cecilia M Fernández-Llamazares, Silvia Manrique-Rodríguez, Álvaro Narrillos-Moraza, Marina García-Morín, Jorge Huerta-Aragonés, María Sanjurjo-Sáez
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 27 Issue 7 Pg. 1753-1757 (Oct 2021) ISSN: 1477-092X [Electronic] England
• PMID: 33356885 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bromocriptine

Topics

• Bromocriptine (therapeutic use)
• Cerebellar Neoplasms (drug therapy, surgery)
• Child
• Humans
• Infratentorial Neoplasms
• Medulloblastoma
• Mutism (drug therapy, etiology)
• Postoperative Complications (drug therapy)